Table 2. Severity of GVHD in BMT... | American Society of Hematology

Table 2.

Severity of GVHD in BMT recipients

Group	Time of analysis (wk)	N	GVHD score (mean ± SEM)
Group	Time of analysis (wk)	N	Liver	Skin	Small intestine	Large intestine
A. Allogeneic BMT → vehicle	2-4	6	2.8 ± 0.1	1.8 ± 0.1	0.8 ± 0.1	1.2 ± 0.4
B. Allogeneic BMT → WHI-P131	> 8	4	1.0 ± 0.3^†	0.5 ± 0.0^‡	0.5 ± 0.0	0.1 ± 0.1^*
C. Allogeneic BMT + BCL-1 → vehicle	2-4	13	2.6 ± 0.1	1.9 ± 0.3	0.7 ± 0.1	1.2 ± 0.2
D. Allogeneic BMT + BCL-1 → WHI-P131	2-4	5	2.0 ± 0.0^*	1.0 ± 0.3^*	0.2 ± 0.1^*	0.5 ± 0.0^*
E. Allogeneic BMT + BCL-1 → WHI-P131	> 8	4	0.6 ± 0.1^‡	0.0 ± 0.0^†	0.3 ± 0.1^*	0.1 ± 0.1^*
F. Syngeneic BMT (control)	2-4	17	0.5 ± 0.0	0.2 ± 0.1	0.3 ± 0.1	0.2 ± 0.1
G. Syngeneic BMT (control)	> 8	5	0.5 ± 0.0	0.0 ± 0.0	0.1 ± 0.1	0.0 ± 0.0

Group	Time of analysis (wk)	N	GVHD score (mean ± SEM)
Group	Time of analysis (wk)	N	Liver	Skin	Small intestine	Large intestine
A. Allogeneic BMT → vehicle	2-4	6	2.8 ± 0.1	1.8 ± 0.1	0.8 ± 0.1	1.2 ± 0.4
B. Allogeneic BMT → WHI-P131	> 8	4	1.0 ± 0.3^†	0.5 ± 0.0^‡	0.5 ± 0.0	0.1 ± 0.1^*
C. Allogeneic BMT + BCL-1 → vehicle	2-4	13	2.6 ± 0.1	1.9 ± 0.3	0.7 ± 0.1	1.2 ± 0.2
D. Allogeneic BMT + BCL-1 → WHI-P131	2-4	5	2.0 ± 0.0^*	1.0 ± 0.3^*	0.2 ± 0.1^*	0.5 ± 0.0^*
E. Allogeneic BMT + BCL-1 → WHI-P131	> 8	4	0.6 ± 0.1^‡	0.0 ± 0.0^†	0.3 ± 0.1^*	0.1 ± 0.1^*
F. Syngeneic BMT (control)	2-4	17	0.5 ± 0.0	0.2 ± 0.1	0.3 ± 0.1	0.2 ± 0.1
G. Syngeneic BMT (control)	> 8	5	0.5 ± 0.0	0.0 ± 0.0	0.1 ± 0.1	0.0 ± 0.0

Scoring was done as described in “Materials and methods.” Statistical analysis of the differences between the groups (B versus A and D versus C and E versus C) was done by Student ttest.

P < .05.

†

P < .005.

‡

P < .0001.

View Large

This Feature Is Available To Subscribers Only